JUN and urinary bladder carcinoma: Isorhapontigenin treatment effectively increased Sestrin2 by allowing JUN to bind to the AP-1-binding region of the Sestrin2 promoter via MAPK8/JNK1, which subsequently enhanced autophagy by converting LC-3I to LC-3II and increased apoptosis in human bladder cancer cells.